Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Borchmann

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Deutsche Medizinische Wochenschrift (1946)|May 31, 2013
[Treatment of advanced Hodgkin lymphoma]S Kreissl, P Borchmann
Der Internist|June 21, 2021
[CAR T-cell therapy for malignant B-cell lymphoma : A new treatment paradigm]H Balke-Want, P Borchmann
Der Internist|July 14, 2001
[Monoclonal antibodies: development and clinical prospects]P Borchmann, G Riethmüller, A Engert
Der Internist|October 1, 1996
[Chronic lymphatic leukemia. Progress in diagnosis and therapy]P Borchmann, V Diehl, A Engert
European Journal of Haematology. Supplementum|July 13, 2005
Immunotherapy of Hodgkin's lymphomaP Borchmann, R Schnell, A Engert
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2002
Current strategies of antibody-based treatment in Hodgkin's diseaseR Schnell, P Borchmann, H Schulz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 1999
New drugs in the treatment of Hodgkin's diseaseP Borchmann, R Schnell, V Diehl, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 1, 1997
Idarubicin: a brief overview on pharmacology and clinical useP Borchmann, K Hübel, R Schnell, et al.
Leukemia & Lymphoma|October 8, 1999
Development of IgG lambda multiple myeloma in a patient with cutaneous CD30+ anaplastic T-cell lymphomaC Wickenhauser, P Borchmann, V Diehl, et al.
Verhandlungen Der Deutschen Gesellschaft Fur Pathologie|January 1, 1993
[Monoclonal antibodies (MIB 1, PC 10, 486p and p53) as prognostic factors for recurrent urothelial carcinoma of the urinary bladder]R Hake, R Vorreuther, P Borchmann, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Deutsche Medizinische Wochenschrift (1946)|May 31, 2013
[Treatment of advanced Hodgkin lymphoma]S Kreissl, P Borchmann
Der Internist|June 21, 2021
[CAR T-cell therapy for malignant B-cell lymphoma : A new treatment paradigm]H Balke-Want, P Borchmann
Der Internist|July 14, 2001
[Monoclonal antibodies: development and clinical prospects]P Borchmann, G Riethmüller, A Engert
Der Internist|October 1, 1996
[Chronic lymphatic leukemia. Progress in diagnosis and therapy]P Borchmann, V Diehl, A Engert
European Journal of Haematology. Supplementum|July 13, 2005
Immunotherapy of Hodgkin's lymphomaP Borchmann, R Schnell, A Engert
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2002
Current strategies of antibody-based treatment in Hodgkin's diseaseR Schnell, P Borchmann, H Schulz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 1999
New drugs in the treatment of Hodgkin's diseaseP Borchmann, R Schnell, V Diehl, et al.
International Journal of Clinical Pharmacology and Therapeutics|February 1, 1997
Idarubicin: a brief overview on pharmacology and clinical useP Borchmann, K Hübel, R Schnell, et al.
Leukemia & Lymphoma|October 8, 1999
Development of IgG lambda multiple myeloma in a patient with cutaneous CD30+ anaplastic T-cell lymphomaC Wickenhauser, P Borchmann, V Diehl, et al.
Verhandlungen Der Deutschen Gesellschaft Fur Pathologie|January 1, 1993
[Monoclonal antibodies (MIB 1, PC 10, 486p and p53) as prognostic factors for recurrent urothelial carcinoma of the urinary bladder]R Hake, R Vorreuther, P Borchmann, et al.
Pageof 5